Table 2.
Continuity test of observed covariates
| Variables | Difference | ||
|---|---|---|---|
| Estimate | 95% CI | P value | |
| Age | −2.7 | −6.4, +0.9 | 0.15 |
| Male sex (%)a | +1.31 | −0.76, +2.39 | 0.73 |
| HCV + HBV (vs others, %)a | +2.10 | −12.0, +16.2 | 0.80 |
| MASLD (vs others, %)a | −3.1 | −9.3, +16.8 | 0.33 |
| ARLD (vs others, %)a | +2.5 | −5.1, 10.0 | 0.61 |
| Serum creatinine | +0.034 | −0.18, +0.25 | 0.76 |
| Serum sodium | −0.58 | −1.99, +0.83 | 0.42 |
| Serum albumin | −0.103 | −0.33, +0.13 | 0.38 |
| Neutrophil count of ascites | −1.93 | −13.1, +9.22 | 0.74 |
| MELD-Sodium score | −0.78 | −4.71, +3.15 | 0.7 |
| MAP | −1.11 | −4.15, +1.93 | 0.48 |
| Amount of ascites removed | 0 | −0.001, +0.001 | 1 |
| Being on diuretics (vs none, %)a | +2.26 | −0.92, +4.48 | 0.4 |
| Being on NSBB (vs none, %)a | −0.87 | −1.86, +1.04 | 0.3 |
| Time to serum test collection from TP (days) | −7.9 | −18.5, 2.7 | 0.14 |
ARLD, alcohol-related liver disease; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; MAP, mean arterial pressure; MASLD, metabolic dysfunction-associated steatotic liver disease; MELD, Model for End-Stage Liver Disease; NSBB, non-selective beta blocker; TP, therapeutic paracentesis.
a
Each 0.5 L increment of ascites was modeled (0–0.4, 0.5–0.9, 1–1.5, and so forth).